Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABD-320
- Development stage
- Unknown
- Lead developer
- Abdera Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABD-320 is a targeted radiopharmaceutical biologic therapy developed by Abdera Therapeutics. It is designed to deliver the alpha-emitting radioisotope Actinium-225 to solid tumors that express an undisclosed target, which is described as widely prevalent and associated with poor outcomes in several cancer types. The therapy was engineered using Abdera’s ROVEr platform to optimize tumor uptake and retention while minimizing systemic radiotoxicity. ABD-320 represents the first therapeutic candidate specifically developed for this particular (undisclosed) target[1][6].
02
Targets
TPBG (Trophoblast glycoprotein)
Beyond the preview
Go deeper on ABD-320.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABD-320.